Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (called OPTICS) looked at people with a type of serious eye inflammation that may be caused by infection. The trial ran in two phases. In Phase I, 100 people took part and 92 completed that phase. In Phase II, participants were split into two groups: 12 people received standard diagnostic care and 9 people had a specialised test called Metagenomic Deep Sequencing (MDS), which analyses genetic material to look for signs of infection. The trial was measuring things like eye improvement, whether treatment was considered appropriate by experts, how certain doctors were about a diagnosis, patients' quality of life, and how well different diagnostic approaches performed. The reported data shows that for the main outcomes in Phase II, 7 out of 12 people in the standard care group and 8 out of 9 in the MDS group showed clinical improvement (such as reduced eye inflammation or better vision scores), while 4 in the standard care group and 1 in the MDS group did not show that improvement. When an independent expert panel judged whether treatment was appropriate, 11 out of 12 in the standard care group and 8 out of 9 in the MDS group were rated as receiving appropriate therapy. On a scale of 0–100% measuring how certain doctors felt about an infection diagnosis, the reported figure was 57.5% for the standard care group and 95% for the MDS group. For patient quality of life (scored 0–100, where higher means better vision function), the reported scores were 62.8 for the standard care group and 75.6 for the MDS group. The reported data from Phase I also compared three different ways of identifying infection. Using a statistical method called Latent Class Analysis — which estimates how well each approach correctly identifies cases — the clinician's own assessment correctly identified around 96% of infection cases but only correctly ruled out infection around 38% of the time. Conventional diagnostic tests correctly identified around 53% of infection cases but correctly ruled out infection around 97% of the time. The MDS test correctly identified around 78% of infection cases and correctly ruled out infection around 89% of the time. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 40653257) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have an eye infection that is causing inflammation inside the eye (such as uveitis affecting the front, middle, or back of the eye, or the whole eye)
- You have a suspected infection inside the eye that developed after eye surgery (known as post-operative endophthalmitis)
- The condition affects one eye or both eyes
- You are 18 years old or older
Who may not be able to join:
- There is not enough eye fluid or tissue sample available for the required testing
- You are under 18 years of age
- You are pregnant
- You are unable to give your own consent to take part in the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Clinical Improvement 2-step Decrease in the Level of Inflammation or Decrease to Grade 0; Inflammatory Retinal/Choroidal Lesions Reducing in Size; 20% Improvement of CST on Optical Coherence Tomography, a > 10- Letter Improvement in Visual Acuity,; Appropriate Therapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.